Vaccine update: Pausing Johnson & Johnson’s (Janssen) COVID-19 vaccine

UI Health Care is following guidance from the Food and Drug Administration and the Centers for Disease Control and Prevention and pausing administration of Johnson & Johnson’s (Janssen) COVID-19 vaccine out of an abundance of caution. 

This pause is a result of six women from the United States who experienced blood clots after receiving this vaccine. While these reports are rare, with more than 6.8 million doses of this vaccine administered in the United States with mild or no side effects, UI Health Care is pausing administration of this vaccine. 

UI Health Care has administered a limited number of the Janssen vaccine, and those individuals will be contacted with information about these recent changes from the FDA.